Virtu Financial LLC raised its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 223.1% in the 4th quarter, Holdings Channel reports. The firm owned 9,357 shares of the life sciences company’s stock after purchasing an additional 6,461 shares during the quarter. Virtu Financial LLC’s holdings in Illumina were worth $2,044,000 at the end of the most recent quarter.
Several other large investors have also added to or reduced their stakes in ILMN. Advisory Services Network LLC lifted its position in shares of Illumina by 13.0% during the second quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock worth $134,000 after purchasing an additional 89 shares during the last quarter. Dupont Capital Management Corp bought a new stake in shares of Illumina during the third quarter worth $153,000. SeaCrest Wealth Management LLC bought a new stake in shares of Illumina during the fourth quarter worth $154,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its position in shares of Illumina by 113.9% during the fourth quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 770 shares of the life sciences company’s stock worth $168,000 after purchasing an additional 410 shares during the last quarter. Finally, Patten Group Inc. lifted its position in shares of Illumina by 71.1% during the third quarter. Patten Group Inc. now owns 1,480 shares of the life sciences company’s stock worth $172,000 after purchasing an additional 615 shares during the last quarter. Institutional investors and hedge funds own 91.12% of the company’s stock.
In other Illumina news, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $211.35, for a total value of $4,227,000.00. Following the transaction, the director now owns 531,717 shares in the company, valued at $112,378,387.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert S. Epstein sold 1,250 shares of Illumina stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $244.18, for a total value of $305,225.00. Following the completion of the transaction, the director now owns 8,588 shares in the company, valued at approximately $2,097,017.84. The disclosure for this sale can be found here. Insiders sold 114,440 shares of company stock worth $25,318,904 in the last quarter. 0.89% of the stock is owned by insiders.
Illumina, Inc. (NASDAQ:ILMN) opened at $229.20 on Monday. Illumina, Inc. has a 52 week low of $158.02 and a 52 week high of $248.97. The company has a quick ratio of 3.55, a current ratio of 3.99 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $33,692.40, a PE ratio of 46.21, a price-to-earnings-growth ratio of 3.03 and a beta of 0.92.
Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.22. Illumina had a return on equity of 21.71% and a net margin of 26.56%. The company had revenue of $778.00 million for the quarter, compared to analyst estimates of $752.04 million. During the same quarter in the previous year, the firm earned $0.85 earnings per share. The firm’s quarterly revenue was up 25.7% compared to the same quarter last year. equities research analysts expect that Illumina, Inc. will post 4.59 EPS for the current fiscal year.
Several research firms have recently weighed in on ILMN. Citigroup upgraded Illumina from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $260.00 to $275.00 in a research report on Monday, February 5th. BidaskClub downgraded Illumina from a “buy” rating to a “hold” rating in a report on Saturday, February 3rd. Barclays lifted their price objective on Illumina from $200.00 to $215.00 and gave the company an “equal weight” rating in a report on Wednesday, January 31st. Morgan Stanley lifted their price objective on Illumina from $145.00 to $157.00 and gave the company an “underweight” rating in a report on Wednesday, January 31st. Finally, Leerink Swann lifted their price objective on Illumina from $250.00 to $276.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. One analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have given a buy rating to the company’s stock. Illumina presently has an average rating of “Buy” and an average price target of $241.39.
COPYRIGHT VIOLATION NOTICE: This report was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.thelincolnianonline.com/2018/02/19/illumina-inc-ilmn-shares-bought-by-virtu-financial-llc.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.